The effect of leucine and nandrolone decanoate supplementation on muscle loss during immobilisatio

Completed

• Conditions: Disuse atrophy; muscle loss; 10028302

• Registration Number: NL-OMON41995
• Lead Sponsor: niversiteit Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2016-05-18
• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

Male
Aged from 18-35 years
18.5 < BMI < 30 kg/m2

Exclusion Criteria

(Family) history of thromboembolic events
Smoking
Recent surgery < 6 months
Performing regular resistance training more than once per week in the past year
Any back/leg/knee/shoulder complaints which may interfere with the use of crutches
Current systemic use of corticosteroids, growth hormone, testosterone, immunosuppressants or insulin
All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis)
Use of anti-coagulants
Pre-existing renal disease or those with a potential risk for renal dysfunction (diabetes, hypertension, reduced glomerular filtration rate)
Liver disease
Heart failure
Use of insulin or blood sugar decreasing medication or EPO
Migraine
Allergy to nuts or soy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Quadriceps CSA</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>whole upper leg muscle CSA<br /><br>muscle fiber type specific CSA<br /><br>muscle fiber type-specific satellite cell content<br /><br>1RM muscle strength</p><br>